Clinical Trials
19 trialsNCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT01198067 2025-09-04
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT04895917 2025-02-20
DarPAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Terminated
NCT04843579 2023-10-25
ClaSPd
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01946152 2021-07-30
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03520985 2021-06-10
OptiPOM
Swiss Cancer Institute
Phase 2 Terminated
NCT03440411 2021-03-10
PO-3887
Fondazione EMN Italy Onlus
Phase 3 Terminated
NCT04243109 2020-01-28
POCODEX
Maimónides Biomedical Research Institute of Córdoba
Phase 2 Terminated
NCT02289222 2019-11-05
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT01979276 2018-06-06
Romi Poma
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT03023527 2018-05-23
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
PETHEMA Foundation
Phase 1 Terminated
NCT01078974 2016-07-25
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01807286 2016-05-13
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01889420 2015-07-31
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT01537861 2015-01-26
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Terminated